Pentasa 2 g granule s produljenim oslobađanjem u vrećici Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

pentasa 2 g granule s produljenim oslobađanjem u vrećici

ferring gmbh, wittland 11, kiel, njemačka - mesalazin - granule s produljenim oslobađanjem u vrećici - urbroj: jedna vrećica sadrži 2 g mesalazina

Enhertu Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Viekirax Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

viekirax

abbvie deutschland gmbh co. kg - Омбитасвир, паритапревир, ritonavir - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - viekirax je indiciran u kombinaciji s drugim lijekovima za liječenje kroničnog hepatitisa c (chc) u odraslih. virus hepatitisa c (hcv) genotip određene aktivnosti .

Deltyba Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

deltyba

otsuka novel products gmbh - Деламанид - tuberkuloza, višestruko otporna - antimikobakterija - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 i 5. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.

Pentasa 500 mg tablete s produljenim oslobađanjem Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

pentasa 500 mg tablete s produljenim oslobađanjem

ferring gmbh, wittland 11, kiel, njemačka - mesalazin - tableta s produljenim oslobađanjem - 500 mg - urbroj: 1 tableta s produljenim oslobađanjem sadrži 500 mg mesalazina

Versatis 700 mg ljekoviti flaster Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

versatis 700 mg ljekoviti flaster

grünenthal gmbh, zieglerstraße 6, aachen, njemačka - lidokain - ljekoviti flaster - 700 mg - urbroj: svaki 10 cm x 14 cm flaster sadrži 700 mg (5% w/w) lidokaina (50 mg lidokaina po gramu ljepljive podloge)

Comirnaty Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Pentasa 1 g tablete s produljenim oslobađanjem Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

pentasa 1 g tablete s produljenim oslobađanjem

ferring gmbh, wittland 11, kiel, njemačka - mesalazin - tableta s produljenim oslobađanjem - urbroj: 1 tableta sadrži 1 g mesalazina

Foster NEXThaler 100/6 mikrograma po inhalaciji, prašak inhalata Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

foster nexthaler 100/6 mikrograma po inhalaciji, prašak inhalata

chiesi pharmaceuticals gmbh, gonzagagasse 16/16, beč, austrija - beklometazondipropionat formoterolfumarat dihidrat - prašak inhalata - 100/6 mikrograma - urbroj: jedna odmjerna doza od 10 mg praška inhalata sadrži: 100 mikrograma beklometazondipropionata i 6 mikrograma formoterolfumarat dihidrata, što odgovara isporučenoj dozi od 81,9 mikrograma beklometazondipropionata i 5,0 mikrograma formoterolfumarat dihidrata.

Pentasa 1 g čepići Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

pentasa 1 g čepići

ferring gmbh, wittland 11, kiel, njemačka - mesalazin - čepić - 1 g - urbroj: 1 čepić sadrži 1 g mesalazina